Company Info

Industry Regional Banks
Sector Finance
Employees 3,317
CEO Mr. Aurelio Alemán-Bermúdez
Address 1519 Ponce de León Avenue Stop 23, San Juan, 00908-0146
Phone 1.787.729.8200

First BanCorp (Puerto Rico) is a holding company, which engages in the provision of personal, commercial, and corporate banking services through its subsidiaries. It operates through the following segments: Commercial and Corporate Banking, Consumer (Retail) Banking, Mortgage Banking, Treasury and Investments, United States Operations, and Virgin Islands Operations. The Commercial and Corporate Banking segment consists of the company's lending and other services for large customers represented by specialized and middle-market clients and the public sector. The Consumer (Retail) Banking segment includes consumer lending and deposit-taking activities conducted mainly through FirstBank's branch network in Puerto Rico. The Mortgage Banking segment focuses on the origination, sale, and servicing of a variety of residential mortgage loan products and related hedging activities. The Treasury and Investments segment deals with treasury and investment management functions. The United States Operations segment represents all banking activities conducted by FirstBank on the United States mainland. The Virgin Islands Operations segment includes all banking activities conducted by FirstBank in the U.S. Virgin Islands and the British Virgin Islands. The company was founded on October 29, 1948 and is headquartered in San Juan, Puerto Rico.


Company Name 3 Month
1 Year
First BanCorp (Puerto Rico) 14.90% 121.92%
Assurant, Inc. 7.19% 34.69%
Credit Acceptance Corp. 30.08% 84.16%
Globe Life, Inc. -0.51% 10.78%
Federal Realty Investment Trust 2.08% 63.63%

Statement Summary

as of 4:10 ET PM 10/21/2021
Total Assets (MRQ) 21.4 B
Total Liabilities (MRQ) 19.2 B
Shareholders’ Equity (MRQ) 2.2 B
Total Revenue (Annual) 232.3 M
Net Income (Annual) 70.6 M

Earnings And Estimates

as of 4:10 ET PM 10/21/2021

Current Qtr EPS Estimate 0.28
Current FY EPS Estimate 1.19
Long Term EPS Growth Estimate 79.48
Next Expected Earnings Date //

FBP vs S&P 500

as of 10/21/2021
Relative To
S&P 500
4 Weeks n/a n/a
12 Weeks n/a n/a
YTD n/a n/a

Earnings Surprises

as of 4:10 ET PM 10/21/2021
Fiscal Quarter Estimate Actual Surprise
06/2021 0.22 0.33 +47.29%
03/2021 0.20 0.28 +36.74%
12/2020 0.18 0.23 +26.19%
09/2020 0.15 0.13 -14.00%
06/2020 0.07 0.09 +27.36%
03/2020 0.16 0.01 -93.67%
12/2019 0.19 0.16 -16.69%
09/2019 0.19 0.21 +8.45%

Financial Strength

as of 4:10 ET PM 10/21/2021
Pre-Tax Margin 47.63
Net Margin 153.28
Operating Margin 0.00
Return On Equity 9.52
Return On Assets 1.19
Inventory Turnover (TTM) 0.00
Sales Growth (MRQ) 2.99


as of 4:10 PM ET 10/21/2021
Price/Earnings (TTM) 14.33
Price/Book (MRQ) 1.33
Price/Cash Flow (TTM) 8.17
Book Value (MRQ) 10.30
Quick Ratio (MRQ) 0.00
Current Ratio (MRQ) 0.45
Total Debt/Equity (MRQ) 0.41

Short Interest

as of 4:10 PM ET 10/22/2021
% Short - 2.59%
% Remaining Float - 97.41%
Current Last Month
Short Interest Date 09/30/2021 09/15/2021
Short Interest Shares 5,244,111 6,582,789
Short Interest Ratio 2.0 4.2
Total Assets 0,0.00 0,0.00
Total Liabilities 0,0.00 0,0.00
Total Equity 0,0.00 0,0.00
Total Revenue 0,0.00 0,0.00
EBT Exc.
Unusual Items
0,0.00 0,0.00
Net Income 0,0.00 0,0.00
Cash from
0,0.00 0,0.00
Cash from
0,0.00 0,0.00
Cash from
Fin. Activities
0,0.00 0,0.00




Balance Sheet

Cash And Equivalents 0,0.00
Receivables 0,0.00
Inventories 0,0.00
Other Current Assets 0,0.00
Total Current Assets 0,0.00
Property, Plant & Equipment, Gross 0,0.00
Accumulated Depreciation & Depletion 0,0.00
Property, Plant & Equipment, Net 0,0.00
Intangibles 0,0.00
Other Non-Current Assets 0,0.00
Total Non-Current Assets 0,0.00
Liabilities & Shareholder Equity
Accounts Payable 0,0.00
Short Term Debt 0,0.00
Total Current Liabilities 0,0.00
Long Term Debt 0,0.00
Deferred Income Taxes 0,0.00
Other Non-Current Liabilities 0,0.00
Minority Interest 0,0.00
Total Non-Current Liabilities 0,0.00
Preferred Stock Equity 0,0.00
Common Stock Equity 0,0.00
Common Par 0,0.00
Additional Paid In Capital 0,0.00
Cumulative Translation Adjustment 0,0.00
Retained Earnings 0,0.00
Treasury Stock 0,0.00
Other Equity Adjustments 0,0.00
Total Capitalization 0,0.00
Total Common Shares Outstanding 0,0.00
Preferred Shares 0,0.00
Treasury Shares 0,0.00
Basic Weighted Shares Outstanding 0,0.00
Diluted Weighted Shares Outstanding 0,0.00
Number Of Employees 0,0.00
Number Of Part-Time Employees 0,0.00


EBT Excluding Unusual Items


Income Statement

Sales 0,0.00
Cost Of Sales 0,0.00
Gross Operating Profit 0,0.00
Selling, General, And Administrative Expenses 0,0.00
Research & Development 0,0.00
Operating Income Before D & A (EBITDA) 0,0.00
Depreciation & Amortization 0,0.00
Interest Income 0,0.00
Other Income - Net 0,0.00
Special Income / Charges 0,0.00
Total Income Before Interest Expenses (EBIT) 0,0.00
Interest Expense 0,0.00
Pre-Tax Income 0,0.00
Income Taxes 0,0.00
Minority Interest 0,0.00
Net Income From Continuing Operations 0,0.00
Net Income From Discontinued Operations 0,0.00
Net Income From Total Operations 0,0.00
Extraordinary Income/Losses 0,0.00
Income From Cum. Effect Of Acct. Change 0,0.00
Income From Tax Loss Carryforward 0,0.00
Other Gains / Losses 0,0.00
Total Net Income 0,0.00
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
Preferred Dividends 0,0.00
Net Income Available To Common 0,0.00
Basic EPS From Continuing Ops. 0,0.00
Basic EPS From Discontinued Ops. 0,0.00
Basic EPS From Total Operations 0,0.00
Basic EPS From Extraordinary Inc. 0,0.00
Basic EPS From Cum Effect Of Accounting Change 0,0.00
Basic EPS From Tax Loss Carryf'd. 0,0.00
Basic EPS From Other Gains (Losses) 0,0.00
Basic EPS, Total 0,0.00
Basic Normalized Net Income/Share 0,0.00
EPS From Continuing Ops. 0,0.00
EPS From Discontinued Ops 0,0.00
EPS From Total Ops. 0,0.00
EPS From Extraord. Inc. 0,0.00
EPS From Cum Effect of Accounting Change 0,0.00
EPS From Tax Loss Carfd. 0,0.00
EPS From Other Gains (L) 0,0.00
EPS, Total 0,0.00
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
Dividends Paid Per Share 0,0.00




Cash Flow Statement

Cash Flow From Operating Activities
Net Income (Loss) 0,0.00
Operating Gains/Losses 0,0.00
Gross Operating Profit 0,0.00
(Increase) Decrease In Receivables 0,0.00
(Increase) Decrease In Inventories 0,0.00
(Increase) Decrease In Other Current Assets 0,0.00
(Decrease) Increase In Other Current Liabilities 0,0.00
(Increase) Decrease In Other Working Capital 0,0.00
Other Non-Cash Items 0,0.00
Net Cash From Continuing Operations 0,0.00
Net Cash From Discontinued Operations 0,0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 0,0.00
Sale Of Property, Plant & Equipment 0,0.00
Cash Used For Investing Activities
Sale Of Short-Term Investments 0,0.00
Purchases Of Property, Plant & Equipment 0,0.00
Acquisitions 0,0.00
Purchases Of Short-Term Investments 0,0.00
Other Cash From Investing Activities 0,0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities 0,0.00
Issuance Of Debt 0,0.00
Cash Used For Financing Activities
Issuance Of Capital Stock 0,0.00
Repayment Of Long-Term Debt 0,0.00
Repurchase Of Capital Stock 0,0.00
Payment Of Cash Dividends 0,0.00
Other Financing Charges, Net 0,0.00
Net Cash From Financing Activities 0,0.00
Effect Of Exchange Rate Changes 0,0.00
Net Change In Cash & Cash Equivalents 0,0.00

Earnings Estimates

as of 4:10 ET PM 10/21/2021
Current Qtr
Next Qtr
Consensus Estimate $0.28 $0.31
# of Estimates 2 2
High Estimate $0.29 $0.31
Low Estimate $0.27 $0.30
Year Ago EPS $0.13 $0.23
Year Over Year Growth Estimate 117.90% 33.91%
Current Yr
Next Yr
Consensus Estimate $1.19 $1.28
# of Estimates 2 2
High Estimate $1.21 $1.38
Low Estimate $1.17 $1.18
Year Ago EPS $0.46 $1.19
Year Over Year Growth Estimate 158.17% 7.76%
Current Qtr
Next Qtr
Current Year
Next Year
Consensus Estimate $0.28 $0.31 $1.19 $1.28
# of Estimates 2 2 2 2
High Estimate $0.29 $0.31 $1.21 $1.38
Low Estimate $0.27 $0.30 $1.17 $1.18
Year Ago EPS $0.13 $0.23 $0.46 $1.19
Year Over Year Growth Estimate 117.90% 33.91% 158.17% 7.76%

Insider Information Summary

as of 09/30/2021
% Insiders - 2.94%
% Remaining Total Shares - 97.06%
Current 1 Month
Net Insider Transaction 18.85 K -38.95 K
Shares Bought 23.62 K 1.05 K
Shares Sold 4.77 K 40.00 K

Insider Activity

Transaction Date Insider/Title Transaction Type Market Value Shares Average Price Current Holdings


Recent Articles from TheStreet

Tesla Model S Plaid Lead

Goldman Cites Tesla, Facebook as Digital Revolution Favorites

Goldman Sachs has put together a list of favored companies that it sees benefiting from 'the broadening of the digital revolution.'

Athira Pharma Lead

Athira Pharma Stock Climbs on Alzheimer's Test as CEO Resigns

Athira Pharma climbs on Alzheimer study news, while the CEO steps down over altered images in her research papers and dissertation.

China's CBD Crackdown Deals Blow To Emerging Market Using Cannabis-derivative In Cosmetics

Luxembourg First European Country to Legalize Cannabis

Luxembourgers will be able to grow up to four cannabis plants in their homes.

Covid-19 Vaccine Lead

CDC Clears Mix-And-Match Booster Shots for Moderna and J&J

A CDC director has signed off on extra doses, and on taking a Covid booster different from the original vaccine, in line with the U.S. FDA recommendations.

Simon Property Goes Public With $22 Billion Bid for Rival Macerich

Simon Property Target Price Up as Bank of America Sees Catalysts

Simon Property firmed after Bank of America increased its price target for the country’s biggest shopping mall REIT to $165 from $150.

Snapchat Lead

5 Top Stock Decliners for Friday: Snap, Beyond Meat, Intel

Snap, Intel, Moderna, Beyond Meat and Honeywell are five stocks that fell on Friday.

27 intel  michelmond : Shutterstock

Intel Stock: One Thing Stands Between It and Another 11% Decline

Intel stock is dropping after its earnings report, but a further 11% decline could be in the cards unless Intel holds a key support level.

Ocular Therapeutix Lead

Ocular Therapeutix Stock Slumps; Dry-Eye Drug Misses Trial Endpoint HOLD

Ocular Therapeutix shares lost a third of their market value after the biopharma's candidate for dry-eye disease missed its key endpoint.

Wall Street Preview: Dollar, Oil and Tech in Focus

Dow Closes at Record High as Powell Cautions on Inflation

The Dow posts its first record close since August as Fed Chair Powell says the central bank was on track to begin tapering the pace of its monthly bond purchases.


5 Top Gainers for Friday: WeWork, Cleveland-Cliffs, American Express

WeWork, Cleveland-Cliffs, American Express, Phunware and Olin are five top gainers for Friday.